BioCentury | May 15, 2020
Product Development

Novartis R&D heads Bradner and Tsai see hard lessons and hope in coronavirus research

If industry had responded to the first SARS outbreak the way it is now, we would probably have drugs on hand to treat COVID-19. That sobering conclusion was evident, said NIBR’s Jay Bradner, when the...
BioCentury | Feb 25, 2020
Distillery Therapeutics

Promoting CX3CL1 expression to treat Alzheimer's

DISEASE CATEGORY: Neurology INDICATION: Alzheimer's disease (AD) Overexpressing the chemokine CX3CL1 could treat AD by preventing neurodegeneration. Neuronal CX3CL1 overexpression boosted neurogenesis in healthy mice and, in mice modeling AD, increased the density and strength...
BioCentury | Jul 2, 2019
Clinical News

Biogen's Spinraza yields long-term preservation of motor development in SMA

Gearing up to compete with a gene therapy in SMA, Biogen presented long-term data from its antisense therapy Spinraza that could help make the case for continued use of the chronic treatment. In the open-label...
BioCentury | May 6, 2019
Distillery Therapeutics

CX3CL1 gene therapy for retinitis pigmentosa

DISEASE CATEGORY: Ophthalmic disease INDICATION: Retinitis Mouse studies suggest CX3CL1 gene therapy could help treat retinitis pigmentosa. In three mouse models of retinitis pigmentosa, CX3CL1 encoded in an adeno-associated viral (AAV) serotype 8 (AAV8) vector...
BioCentury | Feb 14, 2019
Finance

HKEX: where East meets West

Unfazed by the shaky start of the Hong Kong stock exchange’s new biotech chapter, HKEX CEO Charles Li thinks its position at the nexus of East and West will underpin its long-term success. With more...
BioCentury | Nov 27, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Viral infection Cell culture and hamster studies identified two mAbs against Andes orthohantavirus envelope glycoprotein that could help treat Andes viral infection. In a HEK cell-based neutralization assay, screening of A. orthohantavirus envelope glycoprotein-binding...
BioCentury | Jun 8, 2018
Preclinical News

Blood test could predict preterm delivery risk

A pair of blood tests measuring cell-free RNA (cfRNA) predicted gestational age with similar accuracy as standard-of-care ultrasound and women's risk of preterm delivery with up to 80% accuracy, according to a Science study from...
BioCentury | Apr 13, 2018
Company News

Novartis to acquire AveXis for $8.7B

Novartis AG (NYSE:NVS; SIX:NOVN) is acquiring gene therapy company AveXis Inc. (NASDAQ:AVXS) for $218 per share, or about $8.7 billion. The price represents an 88% premium to AveXis' close of $115.91 on April 6, before...
BioCentury | Apr 9, 2018
Company News

Novartis to acquire AveXis for $8.7B

Novartis AG (NYSE:NVS; SIX:NOVN) is acquiring gene therapy company AveXis Inc. (NASDAQ:AVXS) for $218 per share, or about $8.7 billion. The price represents an 88% premium to AveXis' close of $115.91 on Friday, before the...
BioCentury | Mar 2, 2018
Clinical News

FDA panel votes against Charleston's pain candidate

FDA’s Anesthetic and Analgesic Drug Products and Drug Safety and Risk Management Advisory Committees voted 19-2 against approval of a resubmitted NDA for Hydexor (CL-108) from Charleston Laboratories Inc. (Jupiter, Fla.) to treat moderate to...
Items per page:
1 - 10 of 228